A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera |
| |
Authors: | James Chloé Ugo Valérie Le Couédic Jean-Pierre Staerk Judith Delhommeau François Lacout Catherine Garçon Loïc Raslova Hana Berger Roland Bennaceur-Griscelli Annelise Villeval Jean Luc Constantinescu Stefan N Casadevall Nicole Vainchenker William |
| |
Institution: | INSERM U362, Institut Gustave Roussy, Paris XI University, PR1, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France. |
| |
Abstract: | Myeloproliferative disorders are clonal haematopoietic stem cell malignancies characterized by independency or hypersensitivity of haematopoietic progenitors to numerous cytokines. The molecular basis of most myeloproliferative disorders is unknown. On the basis of the model of chronic myeloid leukaemia, it is expected that a constitutive tyrosine kinase activity could be at the origin of these diseases. Polycythaemia vera is an acquired myeloproliferative disorder, characterized by the presence of polycythaemia diversely associated with thrombocytosis, leukocytosis and splenomegaly. Polycythaemia vera progenitors are hypersensitive to erythropoietin and other cytokines. Here, we describe a clonal and recurrent mutation in the JH2 pseudo-kinase domain of the Janus kinase 2 (JAK2) gene in most (> 80%) polycythaemia vera patients. The mutation, a valine-to-phenylalanine substitution at amino acid position 617, leads to constitutive tyrosine phosphorylation activity that promotes cytokine hypersensitivity and induces erythrocytosis in a mouse model. As this mutation is also found in other myeloproliferative disorders, this unique mutation will permit a new molecular classification of these disorders and novel therapeutical approaches. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|